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Targeting neddylation induces DNA damage and
checkpoint activation and sensitizes chronic
lymphocytic leukemia B cells to alkylating agents
C Paiva1,5, JC Godbersen2,5, A Berger3, JR Brown4 and AV Danilov*,1
Microenvironment-mediated upregulation of the B-cell receptor (BCR) and nuclear factor-κB (NF-κB) signaling in CLL cells
resident in the lymph node and bone marrow promotes apoptosis evasion and clonal expansion. We recently reported that
MLN4924 (pevonedistat), an investigational agent that inhibits the NEDD8-activating enzyme (NAE), abrogates stromal-mediated
NF-κB pathway activity and CLL cell survival. However, the NAE pathway also assists degradation of multiple other substrates.
MLN4924 has been shown to induce DNA damage and cell cycle arrest, but the importance of this mechanism in primary neoplastic
B cells has not been studied. Here we mimicked the lymph node microenvironment using CD40 ligand (CD40L)-expressing stroma
and interleukin-21 (IL-21) to find that inducing proliferation of the primary CLL cells conferred enhanced sensitivity to NAE
inhibition. Treatment of the CD40-stimulated CLL cells with MLN4924 resulted in deregulation of Cdt1, a DNA replication licensing
factor, and cell cycle inhibitors p21 and p27. This led to DNA damage, checkpoint activation and G2 arrest. Alkylating agents
bendamustine and chlorambucil enhanced MLN4924-mediated DNA damage and apoptosis. These events were more prominent in
cells stimulated with IL-21 compared with CD40L alone, indicating that, following NAE inhibition, the culture conditions were able
to direct CLL cell fate from an NF-κB inhibition to a Cdt1 induction program. Our data provide insight into the biological
consequences of targeting NAE in CLL and serves as further rationale for studying the clinical activity of MLN4924 in CLL,
particularly in combination with alkylating agents.
Cell Death and Disease (2015) 6, e1807; doi:10.1038/cddis.2015.161; published online 9 July 2015
The ubiquitin–proteasome system ensures timely destruction
of intracellular proteins. In the past decade, protein degrada-
tion has become a pharmacologic target: proteasome
inhibitors (e.g., bortezomib) are currently being used in
therapy of plasma and B-cell neoplasms. Inhibiting the
ubiquitination process upstream of the proteasome represents
a promising alternative approach. In this regard, ubiquitin-like
modifiers (Ubl) such as NEDD8, ISG15 (interferon-stimulated
gene 15), and SUMO (small ubiquitin-like modifier) regulate
diverse cellular processes, depending on the exact Ubl and
substrate involved. One such Ubl, NEDD8, modulates Cullin-
RING E3 ubiquitin ligase (CRL) activity through covalent
modification, neddylation.1
Chronic lymphocytic leukemia (CLL) B cells are highly
dependent on cell–cell interactions in the lymph node and
bone marrow microenvironment.2 Stromal-mediated upregu-
lation of B-cell receptor (BCR) and nuclear factor-κB (NF-κB)
signaling in CLL cells resident in these niches ensures
apoptosis evasion and promotes proliferation and clonal
expansion.3 We recently reported that MLN4924 (pevonedi-
stat), an investigational inhibitor of the NEDD8-activating
enzyme (NAE), successfully abrogates NF-κB pathway
activity, CLL cell survival and chemoresistance in an
in vitro co-culture model that mimics the lymph node
microenvironment.4 NAE adenylates NEDD8 at its C-terminus
and allows its transfer to a specific cysteine within NAE, thus
initiating a process of neddylation. Active NEDD8 is then
transferred to the cysteine of the ubiquitin-conjugating enzyme
(E2) specific for the pathway (Ubc12), and is finally conjugated
to the CRLs.5 CRLs are responsible for ubiquitination and
degradation of their substrate proteins. NAE–NEDD8 interac-
tion is disrupted when a covalent adduct is formed between
NEDD8 and MLN4924.6 Ultimately, this prevents ubiqitination
of CRL target proteins, extending their half-life, thereby
increasing levels of inhibitor of NF-κB (IκB), a negative
pathway modulator.6–8 However, CRLs process a variety
of proteins that, in addition to signal transduction
(IκBα, DEPTOR, β-catenin, hypoxia-inducible factor-1α) and
apoptosis (NOXA, BimEL), are important regulators of cell
cycle andDNA replication (e.g., p21Cip1, p27Kip1,Wee1, Cyclin
D1 and Cdt1).9–14 Because of the diversity of CRL target
substrates, the biological consequences of their inhibition are
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tissue dependent. In adherent solid tumor cell lines, inhibition
of neddylation resulted in characteristic deregulation of cell
cycle with DNA re-replication, checkpoint activation and cell
cycle arrest, thought to be secondary to stabilization of the
replication-licensing protein Cdt1 (chromatin licensing and
DNA replication factor 1) and cyclin-dependent kinase (CDK)
inhibitor p21Cip1.11,15–17 However, the importance of this
mechanism in primary neoplastic B cells has not been studied.
Here we determined that, under the conditions promoting cell
replication and growth, MLN4924 induces checkpoint activa-
tion and cell cycle arrest in primary CLL B -cells. This
mechanism complements abrogation of NF-κB pathway
activity to induce apoptosis in CLL.
Results
CLL cells induced to proliferate exhibit greater sensitivity
to MLN4924. Growth restriction and apoptosis following
inhibition of NEDD8-activating enzyme in solid tumor cell
lines occurs because of DNA re-replication and damage, yet
it is not known whether this occurs in primary lymphoid
tumors. CLL cells obtained from peripheral blood rest in
G0/G1 and undergo spontaneous apoptosis when devoid of
their supportive microenvironment. Hence, to mimic the
lymph node microenvironment and induce CLL cell prolifera-
tion in vitro, we deployed co-cultures with CD40 ligand
(CD40L)-expressing stroma, as previously described by us
and others.4,18 Under these conditions, o1% of cells entered
S phase as early as 24 h, as evidenced by EdU incorporation
(Figure 1a). We then further induced CLL cell proliferation by
means of CpG oligodeoxynucleotide (CpG-ODN), a Toll-like
receptor agonist,19 or interleukin-21 (IL-21). Whereas IL-21
induced apoptosis of the CLL cells outside of their protective
niche,20 CD40L-stimulated CLL cells may be induced to
proliferate in its presence.21 Despite intersample variation at
earlier time points, up to 20% of CLL cells proliferated after a
continuous 72 h exposure to either 1.5 μM CpG-ODN or
25 ng/ml IL-21 (Figure 1a).
To determine whether NAE inhibition influences survival of
the CLL cells that are forced to enter cell cycle, cells were co-
cultured with CD40L-expressing stroma for 72 h with or
without IL-21, and treated with MLN4924 for 8 or 24 h. IL-21
enhanced CLL cell sensitivity to MLN4924. A total of
63.7%±2.6 and 44.4±5.4% underwent apoptosis after a
24 h treatment with 1 μM MLN4924 in the presence or not of
IL-21, correspondingly (P=0.00004; Figure 1b). Similar
findings were observed when CpG-ODN was employed
(Supplementary Figure S1A). In contrast, CD3+ and CD19+
cells isolated from healthy donors exhibited minimal sensitivity
to MLN4924 under the same conditions (Supplementary
Figure S2A). Thus, CLL cells treated with either IL-21 or
CpG-ODN demonstrated enhanced sensitivity to MLN4924.
MLN4924 deregulates Cdt1 and induces DNA damage
and checkpoint activation in CD40L-stimulated CLL
cells. We supposed that the proliferative CLL cell fraction
was sensitized to MLN4924. As re-replication is a well-
established consequence of NAE inhibition and results from
deregulation of Cdt1 function, we then studied Cdt1 in CLL.
Indeed, early accumulation of Cdt1 occurred in a dose-
dependent manner in the CD40L-stimulated cells treated with
MLN4924 (Figure 2a). Cdt1 was also overexpressed in cells
stimulated with IL-21 or CpG-ODN (Figure 2a and
Supplementary Figure S1B). In contrast, Cdt1 levels
remained undetectable in CLL cells cultured off stroma
(Supplementary Figure S3). Because IL-21 was more reliable
at inducing proliferation than CpG-ODN, we used it in our
subsequent experiments.
As overexpression of Cdt1 has been shown to induce DNA
re-replication followed by head-to-tail collision of replication
forks,22 we tested whether checkpoint activation occurred in
CLL cells under these conditions. Indeed, cells treated with
MLN4924 exhibited an early rise in markers of DNA damage,
such as phosphorylation of H2AX (phospho-histone 2A.X) and
replication protein A (RPA), and these events preceded
caspase cleavage of poly-ADP ribose polymerase (PARP;
Figure 2a). These changes were evident at an earlier time
point (4 h) in cells co-stimulated with IL-21, likely indicating a
higher fraction of cells progressing through cell cycle and thus
susceptible to DNA damage. Indeed, we determined that CLL
cells undergoing proliferation (as evidenced by expression of
Ki-67) succumbed to DNA damage (Figure 2b). In contrast,
we observed no evidence of Cdt1 accumulation and DNA
damage in normal PBMCs (Supplementary Figure S2B).
Furthermore, DNA damage induced checkpoint activation in
CLL cells, and this was particularly evident in IL-21-treated
cells. Interestingly, both checkpoint kinases 1 and 2 (Chk1 and
Chk2) were phosphorylated in the presence of MLN4924,
further suggesting that targeting NAE induced activity of both
ATM (ataxia telangiectasia mutated) and ATR (ataxia telan-
giectasia and Rad3 related) activity in CLL cells (Figure 2a). To
confirm the role of Cdt1 in checkpoint activation, we performed
genetic knockdown of Cdt1 in CD40L/IL-21-stimulated CLL
cells and treated them with MLN4924. This manipulation
resulted in reduced DNA damage and Chk1 activation as
evidenced by immunoblotting and immunostaining, as well as
decreased apoptosis (Figure 3 and Supplementary Figure S4).
Degradation of a dual-specificity phosphatase cell division
cycle 25A (Cdc25A) involved in G2/S transition is also CRL
dependent.23 Chk1 phosphorylates and inactivates Cdc25A,
thereby inhibiting CDK1 activity and cell cycle progression.
Treatment with MLN4924 led to increased Cdc25A levels,
whereas the levels of Wee1, another CRL target and a
negative CDK1 regulator, did not consistently change in CLL
cells in the presence of MLN4924 (Figure 2a).
We further analyzed whether Cdt1 accumulation and
checkpoint activation in response to NAE inhibition was
accompanied by cell cycle deregulation in CD40L-stimulated
CLL cells. As expected, stimulation with IL-21 led to an
increase in the number of cells in S and G2/M phases of cell
cycle (Figure 4a; P=0.0001 and P=0.0003, correspondingly).
Furthermore, treatment with MLN4924 caused a pronounced
accumulation of cells in G2/M phases of cell cycle; an S phase
increase was observed in CD40L-only-stimulated cells
(Figure 4a). Although CLL cells demonstrated a dose-
dependent increase in 44N DNA content, such extensive
overreplication was less pronounced in primary lymphoid cells
than previously reported in cell lines treated with MLN4924
(Figure 4b).15
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The above data strongly suggested that Cdt1-mediated DNA
re-replication and checkpoint activation contribute to the
mechanism of action of MLN4924 in proliferating CLL cells.
Therefore, we interrogated CLL cells resident in different
phases of cell cycle for early evidence of apoptosis. Indeed,
21.4±5.1% of cells in G2/M phases of cell cycle demonstrated
caspase-3 cleavage after an 8-h exposure to 1 μMMLN4924 as
comparedwith 10.9±2.6% of cells resting in G0/G1 (Figure 4c).
Thus, targeting NAE in primary CLL cells induces aberrant Cdt1
accumulation with ensuing DNA damage, cell cycle deregula-
tion and accelerated apoptosis of cells induced to proliferate.
NAE inhibition deregulates endogenous CDK inhibitors
in CLL cells. A number of other relevant proteins regulate
cell cycle and are targets of CRL-mediated ubiquitination.
p27Kip1 and p21Cip1 are endogenous CDK inhibitors that bind
to Cyclin-CDK2/CDK1/CDK4/6 complexes and thus regulate
cell cycle progression at G1/S checkpoint. Importantly,
p21Cip1 also has a defined role in G2 checkpoint sustenance
after DNA damage.24 Hence, we evaluated whether NAE
inhibition deregulates endogenous CDK inhibitors, thus
enhancing apoptosis in CLL. We found that baseline
p27Kip1 and p21Cip1 protein levels were low in CD40L-
stimulated cells, and additional stimulation with IL-21 had
no effect (Figure 5a). Following NAE inhibition, both
endogenous CDK inhibitors were upregulated in CD40L-
stimulated CLL cells, but not in cells cultured off stroma
(Figure 5a and Supplementary Figure S3).
As CIP/KIP CDK inhibitors promote dephosphorylated state
of pocket proteins (retinoblastoma (Rb), p107 and p130)
thereby exercising control over G1/S transition, we evaluated
whether they might play a role in G1/S checkpoint activation in
CLL cells treated with MLN4924. Rb protein was hyperpho-
sphorylated in cells stimulated with IL-21, possibly indicating
the fact that a larger fraction of cells progressed through cell
cycle under these conditions (Figure 5a).We did not observe a
change in Rb phosphorylation in CD40L-stimulated cells at
early time points of incubation with the drug (4 and 8 h).
Meanwhile, late hypophosphorylation of Rb at 24 h could be a
result of cell apoptosis (Figure 5a). Finally, knockdown
of either p27Kip1 or p21Cip1 had no effect on γH2AX, Chk1







Figure 1 CLL cells induced to proliferate are sensitized to MLN4924. (a) CLL cells (N= 4) were co-cultured with CD40L-expressing stroma for up to 72 h in the presence or
not of 25 ng/ml IL-21 or 1.5 μM CpG-ODN. Cells were collected daily, labeled with 5-ethynyl-2´-deoxyuridine (EdU) and assayed by flow cytometry. Data are mean±S.E.
A representative image is shown. (b) CLL cells were co-cultured with CD40L-expressing stroma in the presence or not of 25 ng/ml IL-21. After 72 h, cells were treated with
0.25–1 μM MLN4924 or vehicle control for the indicated time intervals. Apoptosis within the CD19+ subset of cells (N= 10) was determined by Annexin V and 7-AAD staining.
*Po0.05 and **Po0.01 compared with CD40L only
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that the endogenous CDK inhibitors play little role in MLN4924-
mediated induction of DNA damage and apoptosis in CLL.
MLN4924 sensitizes CLL cells to the alkylating agents.
We further explored the interaction between MLN4924 and
the chemotherapy agents commonly used in treatment of
CLL, bendamustine and chlorambucil. Although these alky-
lating agents induce DNA crosslinking and DNA damage at
all phases of the cell cycle, they are most toxic to cells that
progress through S phase. As targeting NAE in CLL induces
DNA damage, we hypothesized that MLN4924 might
sensitize CLL cells to the alkylating agents through this
mechanism, where DNA damage might overwhelm DNA
repair mechanisms.
AlthoughCD40L-stimulated CLL cellswere resistant to either
bendamustine or chlorambucil alone, treatment with MLN4924
resensitized them to both agents (Figure 6a). Furthermore, the
cooperative effect of bendamustine and MLN4924 was
enhanced in the presence of IL-21 (Figure 6b). Although
treatment with bendamustine alone led to minimal DNA
damage in the CLL cells cultured on the CD40L-expressing
stroma, both single- and double-strand DNA damage was
enhanced in the presence of both drugs, evidenced by
phosphorylation of RPA, H2AX and p-NBS1 (Figure 6c).
Although re-replication and G2 arrest described above were
evident in the presence of MLN4924 and, to a lesser extent,
bendamustine, the drug combination-mediated DNA damage
was not due to an increase in either of these events (Figure 6d).
Figure 2 CLL cells undergo DNA damage and checkpoint activation in response to treatment with MLN4924. (a) CLL cells were co-cultured with CD40L-expressing stroma in
the presence or absence of 25 ng/ml IL-21 for 72 h. Thereafter, cells were treated with 0.05–1 μMMLN4924 or vehicle control, collected at the indicated time points and subjected
to immunoblotting. Images representative of four independent experiments are shown. (b) CLL cells (N= 4) were co-cultured as above with 25 ng/ml IL-21 followed by a 6-h
incubation with 1 μMMLN4924. Cells were immunostained with γH2AX and Ki-67 antibodies. Nuclei were counterstained with 4,6-diamino-2-phenylindole. A representative case
is shown
Figure 3 NAE inhibition-induced DNA damage and apoptosis are Cdt1 dependent. CLL cells were transfected with the individual siRNAs against Cdt1 or control siRNA using
Amaxa program X-005. Immediately after nucleofection, cells were cultured in the presence of 25 ng/ml IL-21 for 72 h. Thereafter, cells were treated with MLN4924 or vehicle
control. (a and b) Upon 24-h incubation with 0.5 μM MLN4924, proteins were lysed and cells were subjected to immunoblotting. Images representative of four independent
experiments are shown. Apoptosis within the CD19+ subset of cells (N= 10) was determined by Annexin Vand 7-AAD staining; results were normalized to vehicle-treated control.
(c and d) Upon 6-h incubation with 1 μM MLN4924 (N= 6), cells were immunostained with γH2AX antibodies. A representative case is shown. Six high-power fields per sample
were scored for expression of γH2AX as described in the Materials and Methods. Data are mean± S.E. **Po0.01 compared with control conditions
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As we have previously demonstrated that MLN4924
induces BH3-only proteins BIM and NOXA in CLL cells,4 and
bendamustine induces NOXA in non-Hodgkin’s lymphoma
cells,25 we investigated whether the cooperative effect of
these two drugs was due to enhanced upregulation of these
pro-apoptotic B-cell lymphoma 2 (BCL2) family members.
However, whereas incubation with MLN4924 led to a dramatic
induction of NOXA andBIM in CLL cells, bendamustine had no
effect, suggesting that this mechanism did not contribute to
toxicity of this drug combination (Figure 6e).
Finally, we have previously shown that inhibiting NAE
effectively induced apoptosis of CLL cells harboring high-risk
features, including del(17p).4 Such patients represent an
ongoing unmet clinical need.26 To determine whether a
combination of bendamustine and MLN4924 may represent a
promising therapeutic approach in this disease category, we
tested cells obtained from patients with del(17p) CLL. Although
bendamustine has also shown preclinical promise in high-risk
CLL,27 we did not observe a cooperative effect between the two
drugs (Figure 6f). This is consistent with lack of clinical efficacy
of bendamustine inCLLwithdel(17p),28 and likely indicates that
its cytotoxicity is dependent on functional p53.
Discussion
A preclinical study by Milhollen et al.8 provided initial rationale
to target neddylation in B-cell malignancies. In line with the
context-specific role of neddylation, the cytotoxic effects of
MLN4924 in diffuse large B-cell lymphoma (DLBCL) cellswere
dependent on the cell of origin. In germinal center B-cell-like
(GC) DLBCL cells, targeting NAE resulted in accumulation of
Cdt1, DNA re-replication and cell cycle arrest in S phase,
reminiscent of the consequences of NAE inhibition in adherent
human colorectal carcinoma HCT116 cells.15,16 In contrast, in
activated B-cell-like (ABC) DLBCL cells, abrogation of
transcriptional activity of NF-κB was the dominant event that
preceded apoptosis.8
We have recently shown that targeting NAE in CLL cells
neutralizes NF-κB through disrupted ubiquitination of IκB
(canonical pathway) and diminished processing of p100 to p52
(noncanonical pathway), as in ABC DLBCL.4 Treatment with
MLN4924 shifted the balance of BCL2 family members toward
the pro-apoptotic BH3-only proteins, with dramatic upregulation
of BIM and NOXA,4 an event of high importance in CLL cells
whose survival is highly dependent on the anti-apoptotic BCL2
family members.29 Disruption of NF-κB activity as a conse-
quence of NAE inhibition is therefore an important mechanism of
MLN4924-induced apoptosis in activated CLL cells that received
stimulation with CD40L or BAFF (B-cell activating factor) in the
stromal niche.30,31 However, niche-resident CLL cells are
exposed to a variety of stimuli beyond those necessary for NF-
κB activation and demonstrate decreased apoptotic priming,
that is, higher threshold of sensitivity to apoptosis via intrinsic
mitochondrial pathway,18 and hence upregulation of the pro-
apoptotic BH3-only proteins may be less deadly.
Although proliferation of theCLL cells in peripheral circulation
is negligible,32 clone renewal may be substantial,33 suggesting
that cells found in the CLL proliferation centers may be
susceptible to MLN4924-mediated cell cycle deregulation.
Here we extend our earlier findings to ascertain that Cdt1
accumulated in CD40L-activated CLL cells treated with
MLN4924. Ensuing re-replication22 leads to DNA damage
and checkpoint activation, contributing to MLN4924 toxicity in
CLL. As S-phase cells demonstrate enhanced susceptibility to
MLN4924-induced DNA re-replication,15 we stimulated CLL
cells with IL-21,21 significantly expanding proliferative cell
fraction, and thus were able to sensitize CLL cells to
MLN4924. A larger proportion of cells showed evidence of
DNA damage and cell cycle arrest when coincubated with
IL-21, potentially relevant to cells induced to proliferate by their
microenvironment in vivo. Importantly, our data also implicate
that changes in culture conditions can switch the cell fate from
an NF-κB inhibition program to a Cdt1 induction program when
NAE is inhibited, as both phenomena are observed on the
same cell background (primary malignant B cell).
We observed that CLL cells predominantly arrested in G2
upon treatment with MLN4924. In contrast, some DLBCL cells
underwent S-phase arrest.8 Interestingly, a recent study
suggested that lower concentrations of MLN4924 induce G2
arrest, whereas saturating doses of the drug cause a delay in
S-phase progression.23 Genetic knockdowns of Cdt2, a
conserved component of CRL4Cdt2 E3 ligase that targets
Cdt1 for degradation, or of geminin, a negative regulator of
Cdt1, lead to G2 arrest.
34,35 Thus, different means of inducing
re-replication may result in activation of either intra-S or G2
checkpoints. It is also possible that the S-phase arrest
observed in DLBCL cells could also have resulted from
disrupted ubiquitination of the CDK inhibitors p21Cip1 and
p27Kip1. In the CLL cells, these proteins accumulated but did
not alter cell fate in response to MLN4924, although their role
in G2/S transition has not been fully explored in this study.
Earlier findings suggested that CLL cells possess DNA
damage repair ability that is highly variable between individual
samples.36,37 However, understanding of DNA repair mechan-
isms in CLL is limited as it was only studied in resting cells
ex vivo. In our work we demonstrate that CLL cells, when
forced to enter cell cycle in stromal co-cultures, are able to
activate DNA damage response. Generation of single- and
double-stranded DNA breaks, as evident by RPA phosphor-
ylation, γH2-AX in response to treatment with MLN4924 and
phospho-NBS1 (predominantly in response to bendamustine)
resulted in activation of Chk1 and Chk2 kinases. Although
bendamustine was minimally toxic in stromal co-cultures,
checkpoint activation was not sufficient to repair DNA damage
induced by the NAE inhibitor. High expression of endogenous
BCL2 may inhibit ribonucleotide reductase activity, thereby
reducing the pool of intracellular dNTPs.38 CLL cells are
Figure 4 NAE inhibition induces cell cycle deregulation in CLL. (a and b) CLL cells were co-cultured with CD40L-expressing stroma in the presence or absence of 25 ng/ml
IL-21 for 72 h. Cells were treated with the indicated doses of MLN4924 or vehicle control for 24 h and assayed for cell cycle profiling as described in the Materials and Methods.
A representative image is shown. (c) CLL cells (N= 6) were cultured as above and assayed for apoptosis (caspase-3 cleavage) within the resting (G0/G1) and cell proliferative
fractions (G2/M) after an 8 h exposure to MLN4924. Data are mean± S.E. *Po0.05 and **Po0.01 compared with untreated control
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known to express high levels of BCL2 protein, and hence may
be particularly sensitive to DNA damage. We therefore argue
that NAE inhibition-mediated replication stress may contribute
to increased apoptotic priming of the CLL cells.
Despite significant advances of targeted therapy in CLL,
chemoimmunotherapy remains a mainstay of treatment in
younger patients, particularly in the upfront setting. Bend-
amustine, a bifunctional alkylating agent, has received wide-
Figure 5 Effect of MLN4924 on CDK inhibitors p21 and p27 in CLL cells. (a) CLL cells were co-cultured with CD40L-expressing stroma in the presence or not of 25 ng/ml
IL-21 for 72 h. Thereafter, cells were treated with 0.05–1 μM MLN4924 or vehicle control, collected at the indicated time points and subjected to immunoblotting. Images
representative of at least four independent experiments are shown. (b) CLL cells were transfected with the individual siRNAs against p21, p27 or control siRNA using Amaxa
program X-05. Immediately after nucleofection, cells were cultured on CD40L-expressing stroma in the presence of 25 ng/ml IL-21 for 72 h, followed by incubation with 0.5 μM
MLN4924 or vehicle control for 24 h. Whole-cell lysates were subjected to immunoblotting. Representative blots of three independent experiments are shown
Figure 6 MLN4924 enhances activity of the alkylating agents in CLL. (a) CLL cells (N= 10) were co-cultured with CD40L-expressing stroma for 24 h, followed by incubation
with the indicated compounds or with vehicle control for 48 h. Apoptosis within the CD19+ subset of cells was determined by Annexin V and 7-AAD staining. (b) CLL cells (N= 8)
were co-cultured with CD40L-expressing stroma in the presence or not of 25 ng/ml IL-21 for 72 h. Thereafter, cells were treated as shown. Cells were collected at the indicated
time points and assayed for apoptosis (data are mean± S.E.). (c) CLL cells were co-cultured with CD40L-expressing stroma for 24 h, followed by incubation with the indicated
drugs or with vehicle control for 24 h. Cells were lysed and subjected to immunoblotting (a representative image out of four independent experiments is shown). (d) CLL cells
(N= 8) were co-cultured with CD40L-expressing stroma in the presence or not of 25 ng/ml IL-21 for 72 h. Thereafter, cells were treated with drugs alone or in combination for 24 h
and assayed by FACS analysis for cell cycle profiling and cell population with more than 4N DNA content. (e) CLL cells were co-cultured with CD40L-expressing stroma 24 h,
treated with the indicated for 24 h and subjected to immunoblotting. A representative image of three independent experiments is shown. (f) Cells with del(17p) (N= 10) or not were
treated with drugs as above for 48 h and assayed for apoptosis as above; cells without del(17p) were lysed after 24 h of incubation with drugs and subjected to immunoblotting.
Data are mean±S.E. **Po0.01 and *Po0.05 compared with either single drug
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spread use in CLL.28,39,40 Bendamustine induces double-
strand DNA damage, purportedly its main mechanism of
toxicity, as well as unique DNA repair responses such as base
excision repair.25,41 In lymphoma cell lines, bendamustine
activated p53 via elevated expression and phosphorylation at
S15,25 a target site of ATM, ATR and DNA-PK. In accordance
with these data, we observed phosphorylation of NBS1
(Nijmegen breakage syndrome 1) in response to bendamus-
tine treatment in CLL cells, consistent with double-stranded
DNA damage. Despite that, CLL cells were resistant to
bendamustine on stroma in the absence of IL-21, indicating
that sufficient DNA repair took place. However, a combination
of MLN4924 and bendamustine significantly augmented the
extent of double-stranded DNA damage and led to enhanced
apoptosis. As bendamustine is particularly efficient in cycling
cells, IL-21 co-stimulation sensitized CLL cells to the drug
combination. Finally, NAE inhibition was shown to impair the
DNA damage response,17,42 providing further potential
explanation for the cooperative action of this drug combination
in CLL. Our findings echo a recent preclinical analysis where
bendamustine-induced DNA damage was enhanced because
of fludarabine-mediated inhibition of DNA repair and abro-
gated the protective effects of stroma.43 Importantly, we show
that MLN4924 in combination with bendamustine did not
enhance apoptosis of the CLL cells with del(17p), suggesting
that although this is a promising therapeutic strategy, it is not
relevant to CLL with defective p53.
In summary, we demonstrate that targeting NAE induces
DNA damage, checkpoint activation and cell cycle arrest in
CLL cells. This, coupled with abrogation of the NF-κB activity,
results in apoptosis and reversal of stromal-mediated protec-
tion. Our study sheds light on the mechanism of action of
MLN4924 in CLL and B-cell malignancies and suggests a new
therapeutic strategy to enhance the efficacy of the alkylating
agents.
Materials and methods
Patient samples, CLL and stromal cell co-cultures. Peripheral blood
was obtained from patients with B-CLL at Dartmouth-Hitchcock Medical Center and
Oregon Health and Science University following approval by the respective
institutional review board and written informed consent of patients, the majority of
whom were previously untreated. Blood was also obtained from six healthy
volunteers. Isolation of peripheral blood mononuclear cells (PBMCs) was performed
using standard Ficoll-Hypaque techniques (Amersham, Piscataway, NJ, USA). Such
CLL samples had 490% CD5+/CD19+ cells, as determined by flow cytometry. CLL
cells were cultured in RMPI-1640 supplemented with 15% fetal bovine serum,
100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 25 mM HEPES,
100 μM non-essential amino acids and 1 mM sodium pyruvate (Lonza, Walkersville,
MD, USA). Ten CLL samples with 17p deletion were obtained from the CLL Center
at Dana-Farber Cancer Institute. All experiments were performed with freshly
isolated CLL cells except the viability assays involving the latter that were performed
with viably frozen cells.
The mouse fibroblast cell line (L cells) engineered to express CD40L (L4.5) was
given to us by Dr. Sonia Neron (Université Laval, Laval, QC, Canada)44 and were
maintained in RPMI-1640 medium with 10% FBS and penicillin–streptomycin. CLL
cells were cultured under standardized conditions on stromal cells as previously
described.4 Briefly, stromal cells were seeded to achieve 80–100% confluence; on the
following day, CLL cells were plated at a 50 : 1 ratio and incubated at 37 °C in 5%
CO2. To induce proliferation, CLL cells were stimulated with 25 ng/ml IL-21
(Cell Signaling, Danvers, MA, USA) or 1.5 μM CpG-ODN (a kind gift from Dr. John
Byrd, Ohio State University, Columbus, OH, USA) for 72 h, treated with drugs
thereafter and assayed for apoptosis, cell cycle distribution or immunoblotting as
detailed below. At harvest, CLL cells were gently washed off the stromal layer. When
collected for protein analysis, CLL cells were transferred to a new plate and incubated
for an additional 60 min to allow reattachment of stromal cells and thus minimize
contamination of CLL cells. Where indicated, cells were also cultured off stroma at the
same density.
Cell viability testing and drugs. CLL cell apoptosis was measured in
duplicate as previously described using the ApoScreen Annexin V Apoptosis Kit.45
Briefly, cells were resuspended in 150 μl of Annexin V binding buffer containing 1 μl
of Annexin V-PE, 1 μl of 7-aminoactinomycin (7-AAD) and 1 μl of CD19-FITC
(Southern Biotech, Birmingham, AL, USA) and CD3-APC antibodies (Miltenyi
Biotec, San Diego, CA, USA), followed by flow cytometry on a MACSQuant (Miltenyi
Biotec). The following drugs were used: MLN4924 (provided by Millennium
Pharmaceuticals Inc., Cambridge, MA, USA), bendamustine, BMS-345541 (Sigma-
Aldrich, St. Louis, MO, USA) and chlorambucil (MP Biomedicals, Solon, OH, USA).
Immunoblotting. Cells were lysed in RIPA buffer (20 mM Tris, 150 mM NaCl,
1% NP-40, 1 mM NaF, 1 mM sodium phosphate, 1 mM NaVO3, 1 mM EDTA, 1 mM
EGTA, supplemented with protease inhibitor cocktail (Roche, Indianapolis, IN, USA),
phosphatase inhibitor cocktail 2 (Sigma-Aldrich) and 1 mM phenylmethanesulfonyl
fluoride). Proteins were analyzed by immunoblotting as previously described.45 The
following antibodies were used: Bim, CDC25A, Chk1, phospho-Chk1 (S345), γH2AX
(S139), PARP and cleaved PARP, p21, p53, phospho-p95/NBS1 (S343), Rb (S780),
Wee1 (all from Cell Signaling); Cdt1 (F-6), p27 (C-19), total Rb (C-15; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), NOXA (Imgenex, San Diego, CA, USA), Rb
(T821; Life Technologies, Carlsbad, CA, USA), β-actin (Sigma-Aldrich), phospho-
RPA32 (S4/S8) (Bethyl, Montgomery, TX, USA) and horseradish peroxidase-
conjugated anti-mouse and anti-rabbit antibodies (Bio-Rad, Hercules, CA, USA).
Immunocytochemistry. 3 × 105 cells were adhered onto polylysine D-coated
coverslips (Sigma-Aldrich) during a 45-min incubation at 37 °C, fixed in 10% formalin
(Fisher Scientific, Pittsburgh, PA, USA) and permeabilized in 1% Triton-X 100 in PBS.
Coverslips were blocked for 30 min in 5% bovine serum albumin (Sigma-Aldrich) in
PBS with 0.1% Tween-20, probed with γH2AX (S139), phospho-RPA32 (S4/S8) or Ki-
67 antibodies (conjugated with AlexaFluor647; Life Technologies) and then with DyLight
488 goat anti-rabbit antibodies (Thermo Scientific, Carlsbad, CA, USA). Coverslips
were mounted with anti-fading ProLong Gold Solution (Life Technologies) with 4′,6-
diamidino-2-phenylindole (DAPI, for nuclear counterstaining). Fluorescent images were
captured with a Zeiss AxioCam MRm camera mounted on a Zeiss Observer.Z1
microscope (Zeiss, Jena, Germany). Cells positive for γH2AX or phospho-RPA were
counted in six high-power fields per condition (×20 magnification) and referenced to the
total number of cells quantified using ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
siRNA-mediated gene silencing. Electroporation of siRNA into CLL cells
was performed using Amaxa Human B-cell Nucleofection Kit (Amaxa, Cologne,
Germany) as previously described.45 Briefly, 1 × 107 PBMCs were mixed with 100 μl
of Amaxa B-cell nucleofector solution, and 2 μg of siRNA was nucleofected using
program X-05. This resulted in transfection efficiency of 30–60% (as determined
with 2 μg pMaxGFP plasmid) and viability of 50–80% cells at 24 h. The following
siRNA sequences were used (sense strand): Cdt1, 5′-GCAAUGUUGGCCAGA
UCAA-3′; p27, 5′-GCAACCGACGAUUCUUCUACUCA-3′; p21, 5′-CUGUACUGUU
CUGUGUCUU-3' (all from Dharmacon, Lafayette, CO, USA).
Cell cycle analysis. 2 × 105 cells were fixed in ice-cold 70% ethanol while
being vortexed, incubated on ice for 15 min, washed in PBS and resuspended in
250 μl of staining solution containing 20 ng/ml propidium iodide, 200 ng/ml RNAse A
(Sigma-Aldrich), 0.1% Triton-X 100 and 1 μl CD19-FITC mAb in PBS. Cells were
incubated for 15 min and submitted to flow cytometry. For concurrent cell cycle and
apoptosis staining, 5 × 106 cells were fixed and permeabilized using the Inside Stain
Kit (Miltenyi Biotec) according to the manufacturer’s instructions. Staining solution
contained 20 ng/ml propidium iodide, 200 ng/ml RNAse A, 1 μl anti-cleaved
caspase-3 antibody (Cell Signaling) and 1 μl DyLight-488 goat anti-mouse
secondary antibody (Thermo Scientific). Cell cycle analysis was performed using
FlowJo software (Tree Star, Ashland, OR, USA).
5-ethynyl-2′-deoxyuridine (EdU) incorporation analysis. At 2 h
before collection, cells were treated with EdU, a thymine analog, to allow for
incorporation in replicating cells. Cells were then collected, washed with PBS, fixed
in 2% paraformaldehyde and stored at 4 °C until analysis. Subsequently, cells were
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processed using Click-iT EdU AlexaFluor 647 Assay Kit (Life Technologies)
according to the manufacturer’s instruction, and subjected to flow cytometry.
Analysis was performed using the FlowJo software.
Statistical analysis. Results of individual experiments were analyzed
using paired and unpaired Student’s t-test, Fisher’s exact test, nonparametric
Mann–Whitney test and Spearman’s r. Statistical analyses were completed
using the GraphPad Prism 6 software package (La Jolla, CA, USA). All tests
were two sided, and data were considered to be statistically significant at
Po0.05.
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